Cingulate Inc. (NASDAQ:CING) Short Interest Update

Cingulate Inc. (NASDAQ:CING) was the recipient of a significant growth in short interest in February. As of February 15th, there was short interest totalling 133,400 shares, a growth of 24.8% from the January 31st total of 106,900 shares. Based on an average daily volume of 141,800 shares, the short-interest ratio is presently 0.9 days. Approximately 4.3% of the company’s stock are short sold.

Institutional Trading of Cingulate

Institutional investors have recently modified their holdings of the stock. AlphaMark Advisors LLC lifted its position in shares of Cingulate by 50,000.0% during the 4th quarter. AlphaMark Advisors LLC now owns 5,010 shares of the company’s stock worth $25,000 after buying an additional 5,000 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Cingulate during the 3rd quarter worth approximately $106,000. Geode Capital Management LLC purchased a new stake in shares of Cingulate during the 4th quarter worth approximately $135,000. Finally, Commonwealth Equity Services LLC lifted its position in shares of Cingulate by 281.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 43,022 shares of the company’s stock worth $212,000 after buying an additional 31,746 shares during the last quarter. Hedge funds and other institutional investors own 41.31% of the company’s stock.

Cingulate Trading Up 1.9 %

NASDAQ CING opened at $3.83 on Friday. Cingulate has a 52 week low of $1.80 and a 52 week high of $20.83. The firm has a 50 day moving average of $4.57 and a two-hundred day moving average of $5.01.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Roth Mkm initiated coverage on shares of Cingulate in a report on Friday, January 10th. They issued a “buy” rating and a $12.00 price objective for the company. Maxim Group upgraded shares of Cingulate from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Cingulate in a report on Thursday. Finally, Roth Capital upgraded shares of Cingulate to a “strong-buy” rating in a report on Friday, January 10th.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.